[go: up one dir, main page]

SI1165044T1 - High potency dihydroergotamine compositions - Google Patents

High potency dihydroergotamine compositions

Info

Publication number
SI1165044T1
SI1165044T1 SI200030460T SI200030460T SI1165044T1 SI 1165044 T1 SI1165044 T1 SI 1165044T1 SI 200030460 T SI200030460 T SI 200030460T SI 200030460 T SI200030460 T SI 200030460T SI 1165044 T1 SI1165044 T1 SI 1165044T1
Authority
SI
Slovenia
Prior art keywords
high potency
dihydroergotamine
compositions
present
dihydroergotamine compositions
Prior art date
Application number
SI200030460T
Other languages
Slovenian (sl)
Inventor
John R. Plachetka
Donna Gilbert
Original Assignee
Pozen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pozen, Inc. filed Critical Pozen, Inc.
Publication of SI1165044T1 publication Critical patent/SI1165044T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The present invention is directed to improved formulations for dihydroergotamine in which the drug is present at a concentration of at least 2.9 mM. The invention encompasses methods for using these formulations in treating patients for migraine headaches and the packaging of formulation into prefilled syringes for self-administration by patients.
SI200030460T 1999-03-26 2000-03-15 High potency dihydroergotamine compositions SI1165044T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12633399P 1999-03-26 1999-03-26
PCT/US2000/006657 WO2000057851A2 (en) 1999-03-26 2000-03-15 High potency dihydroergotamine compositions
EP00917926A EP1165044B1 (en) 1999-03-26 2000-03-15 High potency dihydroergotamine compositions

Publications (1)

Publication Number Publication Date
SI1165044T1 true SI1165044T1 (en) 2004-10-31

Family

ID=22424248

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030460T SI1165044T1 (en) 1999-03-26 2000-03-15 High potency dihydroergotamine compositions

Country Status (25)

Country Link
US (2) US6495535B1 (en)
EP (1) EP1165044B1 (en)
JP (1) JP2002540136A (en)
CN (1) CN1187039C (en)
AT (1) ATE269056T1 (en)
AU (2) AU763568B2 (en)
CA (1) CA2368587A1 (en)
CZ (1) CZ20013455A3 (en)
DE (1) DE60011589T2 (en)
DK (1) DK1165044T3 (en)
EA (1) EA004307B1 (en)
EE (1) EE200100500A (en)
ES (1) ES2222895T3 (en)
GE (1) GEP20053473B (en)
HK (1) HK1045463B (en)
HR (1) HRP20010780A2 (en)
HU (1) HUP0200641A3 (en)
IL (1) IL145550A0 (en)
MX (1) MXPA01009658A (en)
PL (1) PL354955A1 (en)
PT (1) PT1165044E (en)
SI (1) SI1165044T1 (en)
SK (1) SK13742001A3 (en)
UA (1) UA70357C2 (en)
WO (1) WO2000057851A2 (en)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE269056T1 (en) * 1999-03-26 2004-07-15 Pozen Inc HIGHLY EFFECTIVE MEDICINAL COMPOSITIONS CONTAINING DIHYDROERGOTAMIN
PT1218049E (en) 1999-07-12 2007-01-31 Capnia Inc Apparatus for relieving headaches, rhinitis and other common ailments
US20060172017A1 (en) 1999-11-08 2006-08-03 Capnia, Incorporated Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
US20070039615A1 (en) 1999-11-08 2007-02-22 Capnia, Incorporated Methods and apparatus for treating rhinitis
DE10043321B4 (en) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Use of a transdermal therapeutic system for the treatment of Parkinson's disease, for the treatment and prevention of premenstrual syndrome and for lactation inhibition
DE10053397A1 (en) * 2000-10-20 2002-05-02 Schering Ag Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases
DE10064453A1 (en) * 2000-12-16 2002-07-04 Schering Ag Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20030008005A1 (en) * 2001-07-05 2003-01-09 R.T. Alamo Ventures, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
FR2837708B1 (en) * 2002-04-02 2005-02-04 Schwarz Pharma Lab USE OF 8'-HYDROXYDIHYDROERGOTAMINE FOR THE MANUFACTURE OF A MEDICINE AGAINST MIGRAINE
EP1644004A4 (en) * 2003-06-20 2010-10-06 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US9265732B2 (en) * 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
MX2009008582A (en) 2007-02-11 2009-10-30 Map Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile.
DE102007014947B4 (en) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilized aqueous solutions of ergoline compounds
CA2713762C (en) 2008-02-07 2016-10-18 University Of Washington Circumferential aerosol device
US20110082150A1 (en) * 2008-02-11 2011-04-07 Robert Owen Cook Headache pre-emption by dihydroergotamine treatment during headache Precursor events
CN102209529A (en) 2008-09-09 2011-10-05 阿斯利康(瑞典)有限公司 Method for delivering a pharmaceutical composition to patient in need thereof
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
PT2493474T (en) * 2009-10-30 2019-11-26 Intratus Inc Methods and compositions for sustained delivery of drugs
WO2012054831A2 (en) 2010-10-21 2012-04-26 Rtu Pharmaceuticals, Llc Ready to use ketorolac formulations
CA2828884C (en) 2011-03-03 2021-04-27 Impel Neuropharma, Inc. Nasal drug delivery device
RU2618084C2 (en) 2011-05-09 2017-05-02 Импел Ньюрофарма Инк. Tips for nasal drug delivery
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CA2895816C (en) 2012-12-21 2021-02-23 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
EP2991713B1 (en) 2013-04-28 2019-06-19 Impel Neuropharma Inc. Medical unit dose container
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
CA2998182A1 (en) 2015-09-10 2017-03-16 Impel Neuropharma, Inc. In-line nasal delivery device
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
AU2018205790B2 (en) 2017-01-04 2020-07-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
JP6186533B1 (en) * 2017-03-31 2017-08-23 ナガセ医薬品株式会社 Process for producing maxacalcitol-containing aqueous preparation
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
WO2019104205A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with dip tube
WO2019104192A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with inlet interface
AU2019205318B2 (en) 2018-01-05 2022-02-03 Impel Pharmaceuticals Inc. Intranasal delivery of dihydroergotamine by precision olfactory device
KR20200118034A (en) 2018-01-05 2020-10-14 임펠 뉴로파마 인코포레이티드 Intranasal delivery of olanzapine by a precision olfactory organ device
US11083712B1 (en) * 2018-03-20 2021-08-10 Relevale, Inc. Low concentration delivery of an ergoline derivative for treatment of a headache
JP2021532098A (en) 2018-07-19 2021-11-25 インペル ニューロファーマ インコーポレイテッド Respiratory tract delivery of levodopa and dopa decarboxylase inhibitors for the treatment of Parkinson's disease
US10532049B1 (en) 2018-08-27 2020-01-14 Pharmaceutical Industries Limited Parenteral unit dosage form of dihydroergotamine
BR112021013244A8 (en) 2019-01-03 2022-10-18 Impel Neuropharma Inc NASAL DRUG DELIVERY DEVICE
EP3969085A4 (en) 2019-05-17 2023-06-21 Impel Pharmaceuticals Inc. Single-use nasal delivery device
US11786512B2 (en) 2019-09-23 2023-10-17 Slayback Pharma Llc Stable pharmaceutical compositions of dihydroergotamine mesylate
CA3151950A1 (en) * 2019-12-23 2021-07-01 Scienture, Inc. Dihydroergotamine mesylate formulations and pre-filled injectors for therapeutic delivery of the same
US12128052B2 (en) 2020-05-28 2024-10-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
WO2022009248A1 (en) * 2020-07-07 2022-01-13 Jordan University Of Science And Technology A pharmaceutical composition for treating migraine headaches and a cosolvent method of preparation thereof
WO2022147155A1 (en) 2020-12-31 2022-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US12005118B2 (en) 2022-05-19 2024-06-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2735587A1 (en) 1977-08-06 1979-02-15 Sandoz Ag STABLE SOLUTIONS AND METHOD FOR THEIR PRODUCTION
US4138565A (en) 1975-05-31 1979-02-06 Sandoz Ltd. Stable solutions and processes for their preparation
DE2554533C3 (en) 1975-12-04 1984-08-30 Sandoz-Patent-Gmbh, 7850 Loerrach Use of dihydroergotamine and heparin
DE2555481C3 (en) 1975-12-10 1985-10-03 Sandoz-Patent-GmbH, 7850 Lörrach Production of stable drop solutions of hydrogenated ergot alkaloids
DE2621906A1 (en) 1976-05-17 1977-12-01 Sandoz Ag NEW THERAPEUTIC MIXTURE AND METHOD FOR PRODUCING IT
YU17780A (en) 1980-01-23 1984-10-31 Lek Tovarna Farmacevtskih Process for preparing a stable solution of ergot alkaloid derivatives
DE3136282A1 (en) 1981-09-12 1983-03-24 Hoechst Ag "METHOD FOR STABILIZING PHOTO-UNSTABLE MEDICINAL PRODUCTS AND STABILIZED MEDICAL PREPARATIONS"
US5169849A (en) * 1982-02-01 1992-12-08 Sandoz Ltd. Nasal pharmaceutical compositions
DE3227122A1 (en) 1982-07-20 1984-01-26 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim STABLE SOLUTIONS OF MOTHER CORNAL CALOIDS
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
FR2663224B1 (en) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa PARENTERAL GALENIC FORM.
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
ATE269056T1 (en) * 1999-03-26 2004-07-15 Pozen Inc HIGHLY EFFECTIVE MEDICINAL COMPOSITIONS CONTAINING DIHYDROERGOTAMIN

Also Published As

Publication number Publication date
CN1347313A (en) 2002-05-01
EP1165044B1 (en) 2004-06-16
EA004307B1 (en) 2004-02-26
HK1045463B (en) 2005-05-13
PL354955A1 (en) 2004-03-22
US20030114476A1 (en) 2003-06-19
AU2003246345B2 (en) 2005-04-14
DK1165044T3 (en) 2004-10-25
MXPA01009658A (en) 2003-06-24
CZ20013455A3 (en) 2003-02-12
CA2368587A1 (en) 2000-10-05
HK1045463A1 (en) 2002-11-29
SK13742001A3 (en) 2002-02-05
UA70357C2 (en) 2004-10-15
EP1165044A2 (en) 2002-01-02
PT1165044E (en) 2004-10-29
HRP20010780A2 (en) 2002-12-31
HUP0200641A3 (en) 2002-09-30
EA200101005A1 (en) 2002-02-28
EE200100500A (en) 2003-02-17
DE60011589D1 (en) 2004-07-22
ES2222895T3 (en) 2005-02-16
ATE269056T1 (en) 2004-07-15
AU763568B2 (en) 2003-07-24
US6495535B1 (en) 2002-12-17
US7060694B2 (en) 2006-06-13
JP2002540136A (en) 2002-11-26
CN1187039C (en) 2005-02-02
AU2003246345A1 (en) 2003-10-09
WO2000057851A3 (en) 2001-01-11
IL145550A0 (en) 2002-06-30
WO2000057851A2 (en) 2000-10-05
DE60011589T2 (en) 2004-11-25
HUP0200641A2 (en) 2002-08-28
GEP20053473B (en) 2005-03-25
AU3882500A (en) 2000-10-16

Similar Documents

Publication Publication Date Title
HK1045463A1 (en) High potency dihydroergotamine compositions.
YU63002A (en) Low dose entecavir formulation and use
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
MY118371A (en) Tetrahydrolipstatin containing compositions
LU91254I2 (en) Daptomycin and its pharmaceutically acceptable derivatives (cubicinr)
HK1054918A1 (en) Compounds and compositions for delivering active agents
MXPA01008611A (en) Compounds and compositions for delivering active agents.
MXPA05013340A (en) Compositions and methods for enhanced mucosal delivery of growth hormone.
MX9606732A (en) Therapeutic compounds.
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
GEP20022824B (en) Antipicornaviral Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treatment
TW221378B (en)
BG106155A (en) Novel derivatives and analogues of galanthamin
GR3036774T3 (en) Compositions containing G-CSF and TNF binding protein.
DE69835461D1 (en) Anti-arrhythmic compositions and methods of treatment
MX9805441A (en) Therapeutic compounds.
ITMI932189A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING N-ACETYL CARNOSINE FOR THE TREATMENT OF CATARACT
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
NZ503027A (en) Use of rifamycin derivative for treating mastitis in a domestic animal
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
EA199901055A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF DEMENTIA
EP1347754A4 (en) Compositions for adhesion prevention
JO2296B1 (en) Substituted pyrroles
MXPA02012957A (en) New formulation.
AU6876001A (en) Medicaments for treating colics